Breaking News Instant updates and real-time market news.

CALM

Cal-Maine Foods

$42.00

-0.7 (-1.64%)

, DPRX

Dipexium Pharmaceuticals

17:31
12/22/16
12/22
17:31
12/22/16
17:31

On The Fly: After Hours Movers

UP AFTER EARNINGS: Cal-Maine Foods (CALM), up 1.2%. ALSO HIGHER: Dipexium Pharmaceuticals (DPRX), up 93.8% after it entered into a definitive merger agreement with PLx Pharma... Progenics (PGNX), up 6.7% after its Phase 3 SPECT/CT trial was cleared to continue... Synergy Pharmaceuticals (SGYP), up 4% after it reported "positive" top-line results from its Phase 3 plecanatide trial. DOWN AFTER EARNINGS: Cintas (CTAS), down 3.2%.

CALM

Cal-Maine Foods

$42.00

-0.7 (-1.64%)

DPRX

Dipexium Pharmaceuticals

PGNX

Progenics

$8.86

-0.02 (-0.23%)

SGYP

Synergy Pharmaceuticals

$4.74

-0.07 (-1.46%)

CTAS

Cintas

$120.09

0.58 (0.49%)

  • 22

    Dec

  • 29

    Dec

  • 29

    Jan

CALM Cal-Maine Foods
$42.00

-0.7 (-1.64%)

07/27/16
SPHN
07/27/16
NO CHANGE
Target $35
SPHN
Equal Weight
Cal-Maine Foods price target lowered to $35 from $45 at Stephens
Stephens analyst Farha Aslam remains cautious on Cal-Maine Foods, citing challenging egg industry fundamentals, including depressed demand. The analyst lowered the firm's price target on the stock to $35 from $45 and keeps an Equal Weight rating on shares.
06/16/16
06/16/16
UPGRADE

Hold
Cal-Maine Foods upgraded to Hold from Underweight at BB&T
BB&T analyst Brett Hundley upgraded Cal-Maine Foods to Hold citing limited downside to shares, reduced expectations, and checks that suggest that flock liquidations are intensifying due to current egg prices.
05/24/16
05/24/16
NO CHANGE

Cal-Maine Foods estimates slashed at BB&T
BB&T cut Cal-Maine Foods estimates for the quarter to a loss of 14c from a profit of 32c and lowered full year estimates to $1.95 from $2.89 for 2017. The firm's analyst said recent price quotes show Southeast white large shell eggs down almost 70-% year-over-year.
11/10/16
GSCO
11/10/16
INITIATION
Target $37
GSCO
Neutral
Cal-Maine Foods initiated with a Neutral at Goldman
Goldman analyst Adam Samuelson initiated Cal-Mine with a Neutral and a $37 price target. The analyst said a near-term cyclical recovery is reflected in valuation.
DPRX Dipexium Pharmaceuticals

10/25/16
RAJA
10/25/16
DOWNGRADE
RAJA
Market Perform
Dipexium downgraded to Market Perform from Outperform at Raymond James
10/25/16
FLTL
10/25/16
DOWNGRADE
FLTL
Hold
Dipexium Pharmaceuticals downgraded to Hold from Buy at Feltl
02/04/16
02/04/16
NO CHANGE

Dipexium Pharmaceuticals reaches 75% enrollment in Phase 3 trial of Locilex
Dipexium Pharmaceuticals' OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials of 180 patients per clinical trial being conducted under a Special Protocol Assessment agreement between the FDA and Dipexium for evaluation of Locilex for the treatment of patients with mild infections of diabetic foot ulcers. The company anticipates completing these trials in 2H16 and is targeting an NDA submission with the FDA in 1H17 and a Marketing Authorization Application submission with the European Medicines Agency in 2H17.
PGNX Progenics
$8.86

-0.02 (-0.23%)

04/05/16
JEFF
04/05/16
NO CHANGE
Target $9
JEFF
Buy
Progenics approvability unchanged by PDUFA delay, says Jefferies
Jefferies analyst Gena Wang believes the approvability of Relistor in opioid-induced constipation is unchanged after the FDA pushed back the drug's action date. She sees a favorable risk/reward for shares of Progenics (PGN) ahead of the PDUFA date and keeps a Buy rating on the shares with a $9 price target. Wang points out that the FDA requested no new data from Progenics partner Valeant (VRX).
10/26/16
AGIS
10/26/16
INITIATION
Target $11
AGIS
Buy
Progenics initiated with a Buy at Aegis
Aegis analyst Jason Wittes initiated Progenics with a Buy and a $11 price target.
06/24/16
06/24/16
NO CHANGE

Needham sees Brexit making EU drug reviews 'less efficient, more expensive'
Needham analyst including Alan Carr, Chad Messer, Danielle Brill and Esther Pang noted that if Article 50 is invoked following the Brexit vote, the European Medicines Agency will need to move out of its current base in London and the U.K. will need to create its own separate regulatory organization for drugs, concluding that Brexit will lead to a "less efficient, more expensive, and potentially lengthier regulatory process" for drug approval in the EU and the U.K. Among the companies that are currently in discussions with the EMA or have drugs under MAA review, Needham lists ACADIA (ACAD) Celator (CPXX), Cempra (CEMP), Gilead (GILD) Intercept (ICPT), Seattle Genetics (SGEN), Valeant (VRX) and Progenics (PGNX).
10/04/16
BMUR
10/04/16
INITIATION
Target $11
BMUR
Buy
Progenics assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Progenics Pharmaceuticals with a Buy rating and lowered his price target for the shares to $11 from $14.
SGYP Synergy Pharmaceuticals
$4.74

-0.07 (-1.46%)

12/12/16
SBSH
12/12/16
NO CHANGE
Target $6.5
SBSH
Neutral
Positive data likely to increase Synergy takeout speculation, says Citi
Citi analyst Liav Abraham believes the positive headline data announced Friday for Synergy Pharmaceuticals' first trial for plecanatide in its second indication, irritable bowel syndrome-constipation, is likely to increase speculation of a takeover. The analyst, however, believes the stock is fully valued at current levels on a stand-alone basis. She views Synergy as a potential takeout target for a larger pharma company and upped her price target for the shares to $6.50 from $4. Abraham keeps a Neutral rating on Synergy.
09/14/16
09/14/16
NO CHANGE

Citi calls Synergy Pharmaceuticals a potential target for Takeda
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
CTAS Cintas
$120.09

0.58 (0.49%)

10/03/16
KEYB
10/03/16
NO CHANGE
Target $135
KEYB
Overweight
Cintas price target raised to $135 on G&K Services synergies at KeyBanc
KeyBanc analyst Joe Box raised his price target on Cintas (CTAS) to $135 from $130 as his analysis leads him to think the $130M-$140M synergy target related to the company's G&K Services (GK) deal may be conservative. While the FTC did issue a "second request" on the deal, Box continues to believe there is a high likelihood that the deal closes.
08/25/16
MACQ
08/25/16
INITIATION
Target $130
MACQ
Neutral
Cintas initiated with a Neutral at Macquarie
Macquarie analyst Hamzah Mazari initiated Cintas with a Neutral and $130 price target.
10/06/16
BRRR
10/06/16
DOWNGRADE
BRRR
Market Perform
G&K Services downgraded to Market Perform from Outperform at Barrington
Barrington analyst Kevin Steinke downgraded G&K Services (GK) to Market Perform saying competitive bids to the price offered by Cintas (CTAS) will not emerge. The analyst views the $97.50 offer price as fair for G&K shareholders.
09/29/16
MSCO
09/29/16
NO CHANGE
Target $87
MSCO
Underweight
Cintas valuation appears full, says Morgan Stanley
Morgan Stanley analyst Toni Kaplan views Cintas (CTAS) valuation as full and expects shares to be pressured as organic growth slows from from a deceleration in uniform employment and waning exuberance for the G&K Services acquisition. Kaplan believes Cintas' cross selling opportunities may have reached a peak and believes the company has largely exhausted geographical expansion. The analyst rates Cintas an Underweight with an $87 price target on shares.

TODAY'S FREE FLY STORIES

DE

Deere

$145.25

6.02 (4.32%)

09:53
11/23/17
11/23
09:53
11/23/17
09:53
Upgrade
Deutsche Bank gets off sidelines, upgrades Deere shares to Buy »

Deutsche Bank analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

08:55
11/23/17
11/23
08:55
11/23/17
08:55
General news
FX Update: USD-CAD vaulted upwards on weak Canadian data »

FX Update: USD-CAD…

08:30
11/23/17
11/23
08:30
11/23/17
08:30
General news
FX Action: The USD index (DXY) logged a one-month low »

FX Action: The USD index…

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:08
11/23/17
11/23
08:08
11/23/17
08:08
Hot Stocks
Tesla CEO highlights 'record time' on Australian ion battery »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:07
11/23/17
11/23
08:07
11/23/17
08:07
Hot Stocks
Tesla completes construction on largest lithium ion battery in Australia »

The South Australian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

, INVA

Innoviva

$13.42

0.01 (0.07%)

07:56
11/23/17
11/23
07:56
11/23/17
07:56
Hot Stocks
GSK, Innoviva submit data to FDA for expanded Trelegy Ellipta label »

GlaxoSmithKline (GSK) and…

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

INVA

Innoviva

$13.42

0.01 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVM

Silvercorp Metals

$2.51

-0.07 (-2.71%)

07:52
11/23/17
11/23
07:52
11/23/17
07:52
Hot Stocks
Silvercorp Metals to buy back up to 5% of shares »

Silvercorp Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$10.00

-0.1 (-0.99%)

07:49
11/23/17
11/23
07:49
11/23/17
07:49
Hot Stocks
Cellcom Israel now second layer company according to Concentration Law »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GASS

StealthGas

$4.07

0.36 (9.70%)

07:06
11/23/17
11/23
07:06
11/23/17
07:06
Recommendations
StealthGas analyst commentary at Jefferies »

StealthGas trades at only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$41.01

4.31 (11.74%)

07:02
11/23/17
11/23
07:02
11/23/17
07:02
Recommendations
Copart analyst commentary at Jefferies »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DE

Deere

$145.25

6.02 (4.32%)

06:56
11/23/17
11/23
06:56
11/23/17
06:56
Upgrade
Deere rating change at Deutsche Bank »

Deere upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DE

Deere

$145.25

6.02 (4.32%)

06:55
11/23/17
11/23
06:55
11/23/17
06:55
Recommendations
Deere analyst commentary at Wells Fargo »

Deere price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

06:40
11/23/17
11/23
06:40
11/23/17
06:40
General news
FX Update: The dollar has remained on a weakening track »

FX Update: The dollar has…

SECO

Seeco Holding

$8.34

0.14 (1.71%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Seeco Holding management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Deutsche Bank to hold a conference »

Thailand SET Corporate…

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

04:25
11/23/17
11/23
04:25
11/23/17
04:25
General news
FX Action: USD-CAD punched out a 10-day low »

FX Action: USD-CAD…

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$180.87

-0.99 (-0.54%)

17:47
11/22/17
11/22
17:47
11/22/17
17:47
Periodicals
Facebook tool to show users which content was Russian propaganda, says Bloomberg »

Facebook will add a tool…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.